Inhibitor Therapeutics
Tampa, Florida, United States · Biotechnology, Healthcare, Health Care
Currently the first line treatment for BCCs on exposed areas such as the face and neck is Mohs Surgery which becomes increasingly challenging and leads to permanent scarring and disfiguration. As patients age as they may undergo hundreds of surgeries. Inhibitor believes that itraconazole has clinically meaningful effects on the BCCs, which led us to recruit a team of five experienced Mohs surgeons
Key facts
- Headquarters
- Tampa, Florida, United States
- Employees
- 3
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (INTI)
- Website
- hedgepathpharma.com
- Company page
Recent activity at Inhibitor Therapeutics
- : SEC 8-K (5.02): On September 15, 2026, Inhibitor Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders where stockholders voted to elect six directors: Francis E. O’Donnell, Samuel J. Sears, Niraj Vasisht, Michelle Yanez, Michael Jerman, and Ronald E. Osman. Each director is elected to serve a one-year term expiring at the 2027 Annual Meeting of Stockholders, or until their earlier death, resignation, or removal. This election reflects the company's governance structure and outlines the new composition of its Board of Directors for the upcoming year.
- : Inhibitor Therapeutics Enters Performance-Based Master Services Agreement with Frameshift Management
- : SEC 8-K (1.01): On October 21, 2025, Inhibitor Therapeutics, Inc. entered into a performance-based master services agreement with Frameshift Management, Inc. Under this agreement, Frameshift will provide consulting services focused on biostatistics, regulatory affairs, business development, and strategic consulting to support Inhibitor's programs targeting basal cell carcinomas in Gorlin’s syndrome. The agreement stipulates that the consultant will be compensated with unvested equity, which is contingent upon meeting certain performance requirements. This collaboration aims to enhance Inhibitor's utilization of its proprietary itraconazole formulation. The agreement is strategically significant as it aligns with the company's focus on innovative treatments for rare diseases.
- : HedgePath Pharmaceuticals, Inc.
Inhibitor Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2016 | Seed | $600K |
Leadership
- R. MD, Director
- Stefan Cross, Director
- W. CPA, Director
- Samuel Jr., Director
- Frank MD, Executive Officer, Director
- Garrison CPA, Executive Officer
- Nicholas Virca, Executive Officer
Verified email and direct lines for Inhibitor Therapeutics’s decision-makers are on Fundz. See plans
Companies similar to Inhibitor Therapeutics
- Lipella Pharmaceuticals · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Elevation Oncology · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Kinnate Biopharma · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Immuneering · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Savara Inc · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
About Inhibitor Therapeutics: questions and answers
What does Inhibitor Therapeutics do?
Currently the first line treatment for BCCs on exposed areas such as the face and neck is Mohs Surgery which becomes increasingly challenging and leads to permanent scarring and disfiguration. As patients age as they may undergo hundreds of surgeries. Inhibitor believes that itraconazole has clinically meaningful effects on the BCCs, which led us to recruit a team of five experienced Mohs surgeons
Where is Inhibitor Therapeutics headquartered?
Inhibitor Therapeutics is headquartered in Tampa, Florida, United States.
How many employees does Inhibitor Therapeutics have?
Inhibitor Therapeutics has about 3 employees.
Has Inhibitor Therapeutics raised funding?
Yes. Fundz has recorded 1 funding event for Inhibitor Therapeutics. The most recent, Seed of $600K, was in Apr 2016.
What is the latest news on Inhibitor Therapeutics?
On Sep 15, 2026, SEC 8-K (5.02): On September 15, 2026, Inhibitor Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders where stockholders voted to elect six directors: Francis E. O’Donnell, Samuel J. Sears, Niraj Vasisht, Michelle Yanez, Michael Jerman, and Ronald E. Osman. Each director is elected to ser
Is Inhibitor Therapeutics a public company?
Yes. Inhibitor Therapeutics is publicly traded under the ticker INTI.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy